S2-E43.1 - Cirrhosis - Challenges in Treating Patients
Send us a text Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis. This conversation focuses on challenges in treating patients with NASH cirrhosis and implications for drug development. Jörn Schattenberg begins by discussing several of the elements that make treating patients with NASH cirrhosis especially challenging because treating cirrhosis is challenging, treating NASH is challenging...
28 Aug 202111min
S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
Send us a text Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forward. Historically, NASH drug development strategy has started in advanced fibrosis with the goal of progressing to cirrhosis next. This episode suggests an entirely different approach. The episode starts by discussing the complexities of treating cirrhosis and evolves into a discussion on why compensated cirrhosis might be the BEST place to a...
26 Aug 202153min
S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
Send us a text Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies. After a simple opening from Roger Green, this conversation includes 4 key elements: Health Policy 1:24 - Arun Sanyal discusses directions that Fatty Live...
22 Aug 202112min
S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
Send us a text Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on the roles fibroblast growth factors (FGFs) play in fat metabolism, appetite and other issues related to Fatty Liver disease. After a simple opening from Roger Green, this conversation includes 4 key elements: 1:06 - Arun Sanyal discusses the different ways that ...
21 Aug 202112min
S2-E42.1 - FGF drugs in Development - A Promising Class of Agents
Send us a text Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on FGF drug development to date. After a simple opening from Roger Green, this conversation includes 4 key elements: 1:05 - Roger Green discusses recent history of FGF agents and podcast episodes discussing them 2:11 - Stephen Harrison discusses the efruxifermin BALANCED ...
21 Aug 202115min
S2-E42 - How Do Fibroblast Growth Factor (FGF) Drugs Work and Why Are They So Important?
Send us a text Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This discussion combines a discussion of the role Fibroblast Growth Factors (FGFs) play in the liver and human body in general, followed by a discussion of what this implies for drug development in general and some of the specific agents currently in testing or market: 0:15 - Opening quotes - Step...
19 Aug 202150min
S2-E41.4 - Reasons To Believe That a Multidisciplinary Fight Against NASH Will Bring Value
Send us a text Co-authors Ken Cusi and Stephen Harrison discuss reasons to be optimistic and activist about the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives and Louise Campbell comments separately. This conversation starts with Stephen Harrison suggesting messages for the government and Roger Green and A...
15 Aug 202120min
S2-E41.3 - Critical Success Factors In the Multidisciplinary Fight Against NASH
Send us a text Co-authors Ken Cusi and Stephen Harrison discuss critical success factors in the multidisciplinary call to action regarding the coming NASH Epidemic while NASH kNOWledge President Anthony Villiotti, Global Liver Institute Director of Global Policy Andrew Scott and Roger Green share their unique personal perspectives and Louise Campbell comments separately. This conversation starts with Roger Green asking what it will take to bring gastroenterologists, endocrinologists, hepatolo...
14 Aug 202112min
